Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.51 |
| ▸ | IKBKB | O14920 | 3/20 | 0.47 |
| ▸ | IDH2 | P48735 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299645 | 0.83 | IKBKB (0.59) | IKBKBHDAC8HDAC6CCNA2CDK2 | |
| SCHEMBL21621267 | 0.83 | IKBKB (0.59) | IKBKBHDAC8HDAC6CCNA2CDK2 | |
| SCHEMBL4488019 | 0.82 | MEN1 (0.48) | IKBKBHDAC8HDAC6CCNA2CDK2 | |
| SCHEMBL13638678 | 0.74 | IKBKB (0.42) | IKBKBHDAC8HDAC6CCNA2CDK2 | |
| SCHEMBL30299497 | 0.74 | VCP (0.45) | IKBKBHDAC8HDAC6VCPABL1 | |
| SCHEMBL3472520 | 0.73 | IKBKB (0.46) | IKBKBROCK2 | |
| SCHEMBL21621306 | 0.72 | CDK4 (0.63) | IKBKBHDAC8MAPK1ROCK2 | |
| SCHEMBL3474378 | 0.71 | ROCK2 (0.49) | IKBKBHDAC8HDAC6ROCK2ABL1 | |
| SCHEMBL3471613 | 0.70 | IKBKB (0.49) | IKBKBCCNA2CDK2ROCK2 | |
| SCHEMBL5316895 | 0.70 | TDP1 (0.63) | IKBKBVCPABL1EGFRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383863-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-11-21 | — | — | US | disclosed |
| WO-2023043292-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | 기초과학연구원 | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383863-A1 | PREPARATION METHOD FOR PYRIMIDINE-2-AMINE | NUDT1, UMPS, DPYD | IDH1 335/4885IKBKB 2476/4885IDH2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.